ASN
SPRY icon

Advisory Services Network’s ARS Pharmaceuticals SPRY Stock Holding History

Advisory Services Network’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27
Closed -$271 – 3918
2025
Q3 		$271 Buy
+27
New +$387 ﹤0.01% 4162

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advisory Services Network's SPRY Position: Q4 2025 in Review

Advisory Services Network sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 27 shares — an estimated $271 sold.

Advisory Services Network first reported a position in SPRY in Q3 2025 and held it in 1 quarter. The position peaked at $271 in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Advisory Services Network reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Advisory Services Network sold 27 ARS Pharmaceuticals shares in Q4 2025, an estimated $271.
  • Advisory Services Network first reported a position in ARS Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Advisory Services Network's ARS Pharmaceuticals position peaked at $271 in Q3 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Advisory Services Network's 13F filing for Q4 2025, filed 17 Feb 2026.